Does the media favor FDMT or MOLN?

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Molecular Partners. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat 4D Molecular Therapeutics' score of 0.39 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MNPR or MOLN more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Molecular Partners N/A -66.62% -54.85%

Does the media prefer MNPR or MOLN?

In the previous week, Monopar Therapeutics had 4 more articles in the media than Molecular Partners. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat Monopar Therapeutics' score of 0.50 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MOLN or TECX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets Molecular Partners N/A -66.62% -54.85% Tectonic Therapeutic N/A -32.33% -30.92%

Does the media refer more to MOLN or ALT?

In the previous week, Altimmune had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Altimmune and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat Altimmune's score of 0.58 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VECT or MOLN?

Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 116.41%. Given Molecular Partners' stronger consensus rating and higher probable upside, analysts clearly believe Molecular Partners is more favorable than VectivBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher earnings and valuation, VECT or MOLN?

VectivBio has higher earnings, but lower revenue than Molecular Partners. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VectivBio N/A N/A N/A N/A N/A Molecular Partners $5.65M 27.66 -$74.41M -$1.94 N/A

Is VECT or MOLN more profitable?

VectivBio's return on equity of 0.00% beat Molecular Partners' return on equity. Company Net Margins Return on Equity Return on Assets VectivBio N/A N/A N/A Molecular Partners N/A -66.62% -54.85%

Molecular Partners (MOLN) Competitors

$3.87 -0.09 (-2.27%)

Closing price 06/30/2026 03:46 PM Eastern

Extended Trading

$3.84 -0.03 (-0.88%)

As of 04:00 AM Eastern

Compare

MOLN vs. FDMT, MNPR, TECX, ALT, and VECT

Should you buy Molecular Partners stock or one of its competitors? MarketBeat compares Molecular Partners with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Molecular Partners include 4D Molecular Therapeutics (FDMT), Monopar Therapeutics (MNPR), Tectonic Therapeutic (TECX), Altimmune (ALT), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry.

How does Molecular Partners compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Molecular Partners has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. 4D Molecular Therapeutics' return on equity of -36.83% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Molecular Partners	N/A	-66.62%	-54.85%

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Molecular Partners. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat 4D Molecular Therapeutics' score of 0.39 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Molecular Partners has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.16	-$140.11M	-$2.57	N/A
Molecular Partners	$5.65M	27.66	-$74.41M	-$1.94	N/A

4D Molecular Therapeutics presently has a consensus target price of $29.88, suggesting a potential upside of 124.62%. Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 116.41%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

4D Molecular Therapeutics beats Molecular Partners on 10 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Monopar Therapeutics had 4 more articles in the media than Molecular Partners. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat Monopar Therapeutics' score of 0.50 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics' return on equity of -12.84% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Molecular Partners	N/A	-66.62%	-54.85%

Monopar Therapeutics has higher earnings, but lower revenue than Molecular Partners. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Molecular Partners	$5.65M	27.66	-$74.41M	-$1.94	N/A

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics currently has a consensus price target of $108.75, suggesting a potential upside of 17.45%. Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 116.41%. Given Molecular Partners' higher probable upside, analysts clearly believe Molecular Partners is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Monopar Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Summary

Monopar Therapeutics beats Molecular Partners on 10 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to Tectonic Therapeutic?

Molecular Partners (NASDAQ:MOLN) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tectonic Therapeutic has lower revenue, but higher earnings than Molecular Partners. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	27.66	-$74.41M	-$1.94	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

Molecular Partners currently has a consensus price target of $8.38, indicating a potential upside of 116.41%. Tectonic Therapeutic has a consensus price target of $79.40, indicating a potential upside of 130.95%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Molecular Partners has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.19, suggesting that its share price is 219% more volatile than the broader market.

In the previous week, Molecular Partners had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.87 beat Molecular Partners' score of 0.93 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Overall Sentiment
Molecular Partners	Positive
Tectonic Therapeutic	Very Positive

Tectonic Therapeutic's return on equity of -32.33% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Tectonic Therapeutic	N/A	-32.33%	-30.92%

Summary

Tectonic Therapeutic beats Molecular Partners on 11 of the 15 factors compared between the two stocks.

How does Molecular Partners compare to Altimmune?

Molecular Partners (NASDAQ:MOLN) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Molecular Partners has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	27.66	-$74.41M	-$1.94	N/A
Altimmune	$40K	14,706.79	-$88.09M	-$0.93	N/A

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Molecular Partners has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-66.62%	-54.85%
Altimmune	-214,860.98%	-42.57%	-35.57%

Molecular Partners currently has a consensus target price of $8.38, indicating a potential upside of 116.41%. Altimmune has a consensus target price of $15.71, indicating a potential upside of 419.48%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Altimmune	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Molecular Partners has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

In the previous week, Altimmune had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Altimmune and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.93 beat Altimmune's score of 0.58 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Altimmune beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Molecular Partners compare to VectivBio?

VectivBio (NASDAQ:VECT) and Molecular Partners (NASDAQ:MOLN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

VectivBio has higher earnings, but lower revenue than Molecular Partners.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	N/A	N/A	N/A	N/A	N/A
Molecular Partners	$5.65M	27.66	-$74.41M	-$1.94	N/A

26.6% of Molecular Partners shares are held by institutional investors. 9.7% of VectivBio shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Molecular Partners had 2 more articles in the media than VectivBio. MarketBeat recorded 2 mentions for Molecular Partners and 0 mentions for VectivBio. Molecular Partners' average media sentiment score of 0.93 beat VectivBio's score of 0.00 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
VectivBio	Neutral
Molecular Partners	Positive

VectivBio's return on equity of 0.00% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
Molecular Partners	N/A	-66.62%	-54.85%

Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 116.41%. Given Molecular Partners' stronger consensus rating and higher probable upside, analysts clearly believe Molecular Partners is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Molecular Partners beats VectivBio on 7 of the 10 factors compared between the two stocks.

Get Molecular Partners News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOLN vs. The Competition

Export

Metric	Molecular Partners	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$159.88M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.99	20.90	27.25	24.87
Price / Sales	27.66	341.80	540.68	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.61	8.75	11.01	6.54
Net Income	-$74.41M	$23.81M	$3.57B	$336.70M
7 Day Performance	1.84%	3.60%	2.31%	2.88%
1 Month Performance	-2.03%	3.72%	1.39%	0.64%
1 Year Performance	4.88%	68.80%	36.71%	31.34%

Molecular Partners Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOLN Molecular Partners	2.835 of 5 stars	$3.87 -2.3%	$8.38 +116.4%	+2.1%	$159.88M	$5.65M	N/A	180	Gap Up
FDMT 4D Molecular Therapeutics	1.8497 of 5 stars	$11.62 +0.2%	$29.88 +157.1%	+258.5%	$607.45M	$88.24M	N/A	120
MNPR Monopar Therapeutics	1.9041 of 5 stars	$88.99 +8.8%	$107.91 +21.3%	+158.8%	$596.23M	N/A	N/A	10	News Coverage Analyst Forecast
TECX Tectonic Therapeutic	3.4062 of 5 stars	$30.72 +0.4%	$79.40 +158.5%	+73.0%	$579.66M	N/A	N/A	120	News Coverage
ALT Altimmune	2.0457 of 5 stars	$2.95 +1.4%	$15.71 +432.7%	-21.8%	$573.69M	$40K	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOLN) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Molecular Partners (MOLN) Competitors

MOLN vs. FDMT, MNPR, TECX, ALT, and VECT

How does Molecular Partners compare to 4D Molecular Therapeutics?

Summary

How does Molecular Partners compare to Monopar Therapeutics?

Summary

How does Molecular Partners compare to Tectonic Therapeutic?

Summary

How does Molecular Partners compare to Altimmune?

Summary

How does Molecular Partners compare to VectivBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Molecular Partners (MOLN) Competitors

MOLN vs. FDMT, MNPR, TECX, ALT, and VECT

How does Molecular Partners compare to 4D Molecular Therapeutics?

Which has more volatility & risk, FDMT or MOLN?

Is FDMT or MOLN more profitable?

Does the media favor FDMT or MOLN?

Do institutionals & insiders have more ownership in FDMT or MOLN?

Which has stronger earnings & valuation, FDMT or MOLN?

Do analysts prefer FDMT or MOLN?

Summary

How does Molecular Partners compare to Monopar Therapeutics?

Does the media prefer MNPR or MOLN?

Is MNPR or MOLN more profitable?

Which has better earnings & valuation, MNPR or MOLN?

Do institutionals & insiders hold more shares of MNPR or MOLN?

Do analysts rate MNPR or MOLN?

Which has more volatility & risk, MNPR or MOLN?

Summary

How does Molecular Partners compare to Tectonic Therapeutic?

Do institutionals & insiders have more ownership in MOLN or TECX?

Which has better valuation and earnings, MOLN or TECX?

Do analysts prefer MOLN or TECX?

Which has more risk and volatility, MOLN or TECX?

Does the media favor MOLN or TECX?

Is MOLN or TECX more profitable?

Summary

How does Molecular Partners compare to Altimmune?

Which has preferable earnings & valuation, MOLN or ALT?

Do institutionals & insiders hold more shares of MOLN or ALT?

Is MOLN or ALT more profitable?

Do analysts prefer MOLN or ALT?

Which has more risk and volatility, MOLN or ALT?

Does the media refer more to MOLN or ALT?

Summary

How does Molecular Partners compare to VectivBio?

Which has higher earnings and valuation, VECT or MOLN?

Do institutionals and insiders have more ownership in VECT or MOLN?

Does the media prefer VECT or MOLN?

Is VECT or MOLN more profitable?

Do analysts recommend VECT or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN vs. The Competition

Molecular Partners Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools